Contact Details:
Tel: 01455 250715 begin_of_the_skype_highlighting FREE 01455 250715 end_of_the_skype_highlighting

What is EPD?

EPD was first used in the early 1960s by Doctor Leonard M. McEwen (who, like any qualified doctor, is listed in the Medical Register, copies of which can be found in local libraries). He found that an injection containing a single dose of grass pollen with a very small amount of beta glucuronidase (an enzyme produced naturally by the body) could be more effective in treating hayfever than a long course of conventional desensitising injections or courses of antihistamines.

Further research by Dr. McEwen has made this treatment extremely effective for all types of allergy and intolerances. Since the dose of allergen needed for EPD is much smaller than that used in conventional desensitising injections, this treatment is also much safer.

What does EPD contain?

Enzyme Potentiated Desensitisation (EPD) consists of two components, an activated enzyme called beta-glucuronidase and a mixture of dilute allergens. Several formulations of allergens can be provided, depending on the condition to be treated.

The two components are mixed immediately prior to injection and administered as an intradermal injection of 0.05ml (about the size of a raindrop), usually in the volar aspect of the forearm.

The components of EPD are manufactured under a specials licence by McEwen Laboratories Ltd. Only doctors who have undergone a specialist course of training in the use of EPD can be supplied with this treatment.

The most common formulations which are used are:
IC - simple inhalant allergens (pollens, moulds, mites and animal danders)
XE - all of the above and a wide range of foods and common food additives
X0 - a dilute form of XE
Dt - some common detergents
T - “terpenes” (oil-soluble perfumes and chemicals)

The high-strength allergen mixtures generally contain about the same amount of each allergen as a normal skin prick test; the low-strength allergens are about a millionfold more dilute than this.

Although anaphylaxis remains a theoretical risk of EPD, so far, in 40 years of use, it has never happened. However, patients are asked to wait in the clinic for at least 30 minutes after each treatment.

Research on EPD has been published in international medical journals. In addition, a white paper has been submitted to the US Congress - The American EPD Study, the largest outcome-based study of any type of immunotherapy ever undertaken. Links to these documents can be found on the Useful Links page.

Friends of EPD, 2, Armadale Close, Hollycroft, Hinckley, Leicestershire, LE10 0SZ. Tel: 01455 250715 begin_of_the_skype_highlighting FREE 01455 250715 end_of_the_skype_highlighting
Friends of EPD All Rights Reserved 2006   |   London web design by longhurstsolutions.com